Drug Approval | April 29, 2026
AbbVie seeks FDA nod for RINVOQ use in severe alopecia areata
After Phase 3 results show major hair regrowth gains
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
The approval was driven by data from the Phase III TULIP-SC trial
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The submission is backed by positive results from the Phase 3 AFFIRM study
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
Subscribe To Our Newsletter & Stay Updated
